Sustained Nonvertebral Fragility Fracture Risk Reduction After Discontinuation of Teriparatide Treatment

• DOI: 10.1359/jbmr.050501
• Publication Date: 2006-04-27T09:09:23Z
• Authors: Richard Prince; Adrien Sipos; Anwar Hossain; Unni Syversen; Sophia Ish-Shalom; Ewa Marcinowska; Johan Halse; Robert Lindsay; Gail P Dalsky; Bruce H Mitlak
• Keywords: Teriparatide; Discontinuation

A follow-up in 1262 women was conducted after the discontinuation of teriparatide. The hazard ratio for combined teriparatide group (20 and 40 microg) 50-month period baseline 0.57 (p = 0.002), suggesting a sustained effect reducing risk nonvertebral fragility fracture.Treatment with [rhPTH(1-34)] 20 microg once-daily subcutaneous dosing significantly reduced fractures over median exposure 19 months.All participants Fracture Prevention Trial were invited to participate study. Prior treatment assignments revealed, patients able receive osteoporosis treatments without restriction.Approximately 60% received an at some time during follow-up, greater use former placebo than < 0.05). ratios each relative statistically significant including 0.03). In period, different between mug groups versus but not placebo. However, from other. Kaplan-Meier analysis fracture showed that incidence diverged 0.009). Total hip femoral neck BMD decreased teriparatide-treated who had no treatment; remained stable or further increased bisphosphonate treatment.While study design is observational, results support up 30 months treatment.